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Visual Abstract
IMPORTANCE Although durable left ventricular assist device (LVAD) therapy has emerged as
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an important treatment option for patients with advanced heart failure refractory to
pharmacological support, outcomes, including survival, beyond 2 years remain
poorly characterized.
OBJECTIVE To report the composite end point of survival to transplant, recovery, or LVAD

support free of debilitating stroke (Modified Rankin Scale score >3) or reoperation to replace
the pump 5 years after the implant in participants who received the fully magnetically
levitated centrifugal-flow HeartMate 3 or axial-flow HeartMate II LVAD in the MOMENTUM 3
randomized trial and were still receiving LVAD therapy at the 2-year follow-up.
DESIGN, SETTING, AND PARTICIPANTS This observational study was a 5-year follow-up of the
MOMENTUM 3 trial, conducted in 69 US centers, that demonstrated superiority of the
centrifugal-flow LVAD to the axial-flow pump with respect to survival to transplant, recovery,
or LVAD support free of debilitating stroke or reoperation to replace the pump at 2 years.
A total of 295 patients were enrolled between June 2019 to April 2021 in the extended-phase
study, with 5-year follow-up completed in September 2021.
EXPOSURES Of 1020 patients in the investigational device exemption per-protocol
population, 536 were still receiving LVAD support at 2 years, of whom 289 received the
centrifugal-flow pump and 247 received the axial-flow pump.
MAIN OUTCOMES AND MEASURES There were 10 end points evaluated at 5 years in the
per-protocol population, including a composite of survival to transplant, recovery, or LVAD
support free of debilitating stroke or reoperation to replace the pump between the
centrifugal-flow and axial-flow pump groups and overall survival between the 2 groups.
RESULTS A total of 477 patients (295 enrolled and 182 provided limited data) of 536 patients
still receiving LVAD support at 2 years contributed to the extended-phase analysis
(median age, 62 y; 86 [18%] women). The 5-year Kaplan-Meier estimate of survival to
transplant, recovery, or LVAD support free of debilitating stroke or reoperation to replace the
pump in the centrifugal-flow vs axial-flow group was 54.0% vs 29.7% (hazard ratio, 0.55
[95% CI, 0.45-0.67]; P < .001). Overall Kaplan-Meier survival was 58.4% in the
centrifugal-flow group vs 43.7% in the axial-flow group (hazard ratio, 0.72 [95% CI,
0.58-0.89]; P = .003). Serious adverse events of stroke, bleeding, and pump thrombosis
were less frequent in the centrifugal-flow pump group.
CONCLUSIONS AND RELEVANCE In this observational follow-up study of patients from the
MOMENTUM 3 randomized trial, per-protocol analyses found that receipt of a fully
magnetically levitated centrifugal-flow LVAD vs axial-flow LVAD was associated with a better
composite outcome and higher likelihood of overall survival at 5 years. These findings
support the use of the fully magnetically levitated LVAD.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02224755 and NCT03982979
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D

espite benefits of pharmacological therapy for chronic
heart failure, some patients exhibit refractoriness to
therapy. Patients with refractory heart failure have
worse quality of life, inability to tolerate drug therapy, and poor
prognosis.1,2 Advanced heart failure may be fatal without use
of a left ventricular assist device (LVAD), cardiac transplant,
or palliative inotropic support. Among available LVADs, the centrifugal-flow HeartMate 3 has been engineered with wide blood
flow pathways, friction-free movement using fully magnetically levitated technology, and intrinsic pulsatility to reduce
shear stress and stasis of blood, while the Heartmate II is a continuous axial-flow pump that requires thoracoabdominal placement. Although LVAD therapy has gained support, clinical outcomes and life prolongation beyond 2 years remain poorly
characterized.3 As a consequence, referrals for LVAD implantation may occur late and with worse end-organ function.
The Multicenter Study of MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy With
HeartMate 3 (MOMENTUM 3) randomized clinical trial demonstrated that the fully magnetically levitated centrifugalflow LVAD, compared with the axial-flow pump, resulted in better outcomes driven by greater hemocompatibility 2 years after
the implant.4 However, the overall survival difference between the treatment group at 2 years did not reach statistical
significance (hazard ratio [HR], 0.88 [95% CI, 0.67-1.16]).4 The
US Food and Drug Administration approved the centrifugalflow pump for lifelong use (destination therapy) in advanced
heart failure in 2018, conditional on an extended evaluation
to 5 years of follow-up among those still receiving LVAD support in the trial.
The purpose of this study was to report the composite end
point of survival to transplant, recovery, or LVAD support free
of debilitating stroke (Modified Rankin Scale score >3) or reoperation to replace the pump 5 years after the implant in participants who received the centrifugal-flow pump or axialflow pump in the investigational device exemption (IDE) trial
and were still receiving LVAD support at the 2-year follow-up.

Methods
Study Design
The IDE trial was designed to compare the safety and effectiveness of the centrifugal-flow pump with the axial-flow pump
in patients with advanced heart failure who were refractory
to pharmacological support through 2 years after the implant
and was conducted at 69 centers in the US (NCT02224755).
Both LVADs are manufactured by Abbott. Patients were
included irrespective of the intended goal of therapy of either
bridge to transplant or destination therapy. As shown in
Figure 1, patients were randomized to the centrifugal-flow
pump or axial-flow pump group (intent-to-treat population).
Between September 2014 and August 2016, a total of 515
patients in the centrifugal-flow pump group and 505 in the
axial-flow pump group underwent implantation of their
assigned study device (per-protocol population). The trial was
originally designed to conclude after 2 years of follow-up, which
occurred in 2018. There were 536 patients (289 in the
1234

Key Points
Question In patients with advanced heart failure, what is the
difference in the composite end point of survival to transplant,
recovery, or left ventricular assist device (LVAD) support free of
debilitating stroke or reoperation to replace the pump 5 years
following implantation of a fully magnetically levitated
centrifugal-flow vs axial-flow LVAD?
Findings This observational 5-year follow-up study included 477
of 536 surviving patients from the MOMENTUM 3 randomized trial
at 2 years. In a per-protocol analysis of patients receiving a fully
magnetically levitated vs axial-flow LVAD, the composite outcome
occurred in 54.0% vs 29.7% of patients (hazard ratio, 0.55) and
overall survival in 58.4% vs 43.7% of patients (hazard ratio, 0.72).
Results of both comparisons were statistically significant.
Meaning Among patients with advanced heart failure, receipt of a
fully magnetically levitated centrifugal-flow LVAD vs axial-flow
LVAD was associated with a better composite outcome and higher
likelihood of overall survival at 5 years.

centrifugal-flow pump group and 247 in the axial-flow pump
group) still receiving LVAD support at the completion of the
2-year follow-up in the pivotal trial. The original trial design,
results, and trial protocol have been previously published.4,5
The US Food and Drug Administration approval for the centrifugal-flow pump long-term indication was granted in
October 2018. As a condition of approval, an observational extended follow-up study of patients still receiving LVAD support in the pivotal trial from 2 to 5 years after the implant was
mandated. This postapproval extended-phase study was conducted under a unique protocol.
The protocol for the postapproval extended-phase study
was separate from that prepared for the original trial and required participating centers to complete the start-up process
as a de-novo study, obtain institutional review board approval, and obtain consent from all patients still receiving LVAD
therapy beyond 2 years (Supplement 1). The study was conducted at the same sites that participated in the pivotal (IDE)
trial. Centers determined their patients’ eligibility for the extended-phase protocol based on medical records at the site.
If a patient died before providing consent (and after 2-year
follow-up), centers could provide the date and cause of death
as part of institutional review board approval. Patients receiving LVAD support who provided consent to the extendedphase follow-up were followed up until 5 years after the implant or a prespecified outcome (death, transplant, explant/
permanent deactivation, or withdrawal), whichever occurred
first. Patients who underwent a device exchange to a pump
other than their study-assigned LVAD were withdrawn. Data
were collected from study visits performed at 3, 4, and 5 years
after the implant. In addition, there were some centers that declined to participate in the extended-phase study protocol;
however, institutional review board approval was obtained for
the centers to provide limited outcome data within 5 years after the implant for their patients (death, transplant, explant,
still receiving LVAD therapy at 5 years, and outcome dates).
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Figure 1. Flow of Patients in a Trial of 5-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices
2744 Adults with advanced heart failure
screened for inclusion
1716 Excludeda
761 Met exclusion criteria
214 Insurance denials
198 Did not consent
142 Did not meet inclusion criteria
68 Not LVAD candidate
333 Other or multiple reasons

1028 Randomizedb

516 Randomized to centrifugalflow pump group

512 Randomized to axial-flow
pump group

1 Withdrawn before implant because of death

7 Withdrawn before implant
2 Died
2 Did not undergo LVAD implant
1 Withdrew consent
1 Received transplant
1 Implanted with nonstudy LVAD

515 Underwent pump implant

505 Underwent pump implant

226 Experienced outcome before 2 y
119 Received transplant
98 Died
6 Withdrawn
3 Change in patient statusc
2 Switch to non–study assigned device
1 Withdrew consent
3 Pump removed or permanently deactivated

258 Experienced outcome before 2 y
137 Received transplant
103 Died
15 Withdrawn
2 Change in patient statusc
11 Switched to non–study assigned device
1 Withdrew consent
1 Transferred care to non–study site
3 Pump removed or permanently deactivated

289 Completed 2-y follow-up

247 Completed 2-y follow-up

31 Withdrawn with no available data beyond 2 y
14 Unable to be reached or to provide consent
for extended follow-up
12 Site declined providing extended follow-up data
5 Transferred care to non–study site

28 Withdrawn with no available data beyond 2 y
7 Unable to be reached or provide consent for
extended follow-up
14 Site declined providing extended follow-up data
5 Transferred care to non–study site
2 Receiving palliative/hospice care

258 With data beyond 2 y contributed
to extended-phase analysisd

219 With data beyond 2 y contributed
to extended-phase analysisd
134 Experienced outcome before 5 y
81 Died
29 Received transplant
22 Withdrawn
15 Did not provide consent for extended
follow-up
7 Switched to non–study assigned device
2 Pump removed or permanently deactivated

117 Experienced outcome before 5 y
58 Died
37 Received transplant
21 Withdrawn
17 Did not provide consent for extended
follow-up
2 Lost to follow-up
1 Transferred care to non–study site
1 Withdrew consent
1 Pump removed or permanently deactivated
141 Completed 5-y follow-up

The investigational device exemption trial followed up patients for 2 years and
the postapproval extended-phase study followed up patients still receiving left
ventricular assist device (LVAD) therapy up to 5 years.
a

Specific inclusion and exclusion criteria were not documented at screening.

b

Patients were randomized in a 1:1 ratio and randomization was stratified by
study center and blocked to maintain the 1:1 ratio over time.

c

Incarceration, nonadherence, suicide attempt/depression, or cancer diagnosis.

jama.com

85 Completed 5-y follow-up
d

A total of 178 patients with magnetically levitated centrifugal-flow pumps and 117
with axial-flow pumps were consented then enrolled in the extended-phase
study protocol. Limited 5-year outcome data were obtained in 63 patients in the
centrifugal-flow pump group and 87 in the axial-flow pump group who were not
successfully enrolled in the extended-phase study. There were 17 patients in the
centrifugal-flow pump group and 15 in the axial-flow pump group who did not
provide consent for extended follow-up and were considered to be alive on the
date of refusal and then censored in the analysis.
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End Points
There were 10 end points assessed in the per-protocol population. The composite end point was survival to transplant, recovery, or LVAD support free of debilitating stroke (Modified
Rankin Scale score >3) or reoperation to replace the pump 5
years after the implant. Other end points included patient outcomes (transplant, explant/permanent deactivation, or withdrawal) and survival and frequency and incidence of serious
adverse events (bleeding [including gastrointestinal bleeding], major infection, hemolysis, device thrombosis and device malfunction, and neurological dysfunction [including
stroke]). Functional status as assessed by New York Heart
Association (NYHA) class and 6-minute walk distance (6MWD)
was also evaluated.

Study Conduct and Analysis Plan Modifications
Due to the gap created by ending the pivotal trial and starting
the extended-phase study, data beyond 2 years could not be
collected in some patients (eg, their site declined to provide
any extended follow-up data, they were unable to be reached
to complete consent, they transferred care to a nonparticipating center) (Figure 1). A total of 295 patients were successfully consented and enrolled under the extended-phase study
protocol from June 2019 to April 2021 (eTable 1 in Supplement 2), and adverse events and functional status assessments could be collected only in these patients. The final 5-year
follow-up visit was completed in September 2021. During the
study follow-up, the COVID-19 pandemic created difficulties
with obtaining NYHA class and 6MWD. Details regarding study
conduct are provided in Supplement 1.
The operational challenges of the extended-phase study reduced the investigators’ ability to assess the original intended
primary end point of the study with completeness, which was
a composite requiring data on the serious adverse event of
stroke. Due to the limitations imposed by missing data, the trial
publication and presentation committee determined that overall survival should serve as the modified principal study end
point because it was least influenced by the operational challenges and offered the most completeness in data collection. Additional post hoc end points were specified, including an analysis in patients who received an LVAD for destination therapy
intent and cause-specific mortality with deaths categorized into
those due to hemocompatibility-related events (stroke, bleeding, and device thrombosis), heart failure (including right ventricular failure), infection, and all other causes. All deaths occurring during the 2-year follow-up of the pivotal trial were
adjudicated by a clinical events committee (98 deaths in the centrifugal-flow pump group and 103 in the axial-flow pump group).
Deaths in patients who successfully consented for extended follow-up were also adjudicated by the clinical events committee
(7 in the centrifugal-flow pump group and 9 in the axial-flow
pump group). Subgroup analyses were performed for categories based on age, sex, race and ethnicity, intended goal of
therapy (bridge to transplant or destination therapy), and severity of illness (based on Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] profile) at
baseline). Race and ethnicity were collected in the trial to inform on the treatment effect across different subgroups and were
1236

self-reported based on predefined categories of Asian, Black,
Native Hawaiian or Pacific Islander, and White race and an open
category for all other.

Statistical Methods
Continuous variables are presented as mean (SD) or median (IQR)
and categorical variables as counts and percentages. The sample
size for the extended phase included patients from the IDE trial
still receiving LVAD support at 2 years who then contributed any
data beyond 2 years for at least 1 end point analysis.
The composite end point of survival to transplant, recovery, or LVAD support free of debilitating stroke or reoperation
to replace the pump was evaluated with the Kaplan-Meier
method and Cox proportional hazards modeling. Proportional hazards assumptions were confirmed by creating and
testing the significance of time-dependent covariates. Events
constituting failure of the composite end point included death,
debilitating stroke, and reoperation. Withdrawals were also
considered failure events; however, in the extended phase this
only applied to patients who were successfully consented for
extended follow-up. Serious adverse events during the extended phase were not collected in all patients contributing
to the analysis cohort, and it was assumed that these patients
had no debilitating stroke after 2 years.
Survival rates were estimated with the Kaplan-Meier
method and HRs with 95% CIs were calculated with Cox proportional hazards modeling. Patients who underwent heart
transplant, device removal/deactivation, or withdrawal were
censored at the time of the outcome. The Fine-Gray model was
used to evaluate mortality risk while accounting for the competing risk of heart transplant and to evaluate cause-specific
mortality as a post hoc analysis. To assess the treatment effect on survival across different subgroups (based on age, sex,
race and ethnicity, intended goal of therapy, and INTERMACS
profile at baseline), an interaction term between the subgroup covariate and the treatment group was included in the
Cox proportional hazards models.
Because outcome data in the extended-phase study were
not able to be collected in all patients who were receiving LVAD
support at 2 years, the robustness of the observed survival rates
in the extended-phase study was evaluated in a post hoc analysis. Missing outcome data from the extended-phase study were
filled in with additional data (occurrence of death, transplant, device explant, including dates of these outcomes,
within 5 years after implant) from the sponsor’s device tracking database as permissible by state regulations. No data from
patients refusing consent for the extended-phase study were
used. A tipping point analysis using δ-adjusted bootstrapbased multiple imputation was implemented to test the assumption of noninformative censoring for the patients remaining withdrawn after inclusion of the supplemental device
tracking data, excluding those undergoing exchange to a non–
study-assigned device. Thirty rounds of imputation were performed and the δ for centrifugal-flow pump was increased by
1 unit each time until the treatment effect in favor of centrifugal-flow pump was no longer significant. In the axial-flow
pump group, the mortality hazard was assumed to be the same
between withdrawn vs patients who were not withdrawn.
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Rates for serious adverse events occurring from 0 to 5 years
are presented in events per patient-year and compared between treatment groups with rate ratios and 95% CIs calculated using Poisson regression. Only patients who consented
for extended follow-up contributed serious adverse events after 2 years (178 in the centrifugal-flow pump group and 117 in
the axial-flow pump group).
Two-sided P values <.05 were considered significant. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be
interpreted as exploratory. All statistical analyses were performed with SAS, version 9.4 (SAS Institute).

Results
Patient Population
In the IDE trial’s per-protocol population of 1020 patients, 515
patients received the centrifugal-flow LVAD and 505 patients
received the axial-flow LVAD (Figure 1). A total of 289 patients in the centrifugal-flow pump group and 247 in the axialflow pump group were still receiving LVAD support at 2 years.
Due to the gap created by ending the pivotal trial and starting
the extended-phase study, there were 59 patients for whom
no data beyond 2 years were able to be collected. The remaining 477 patients had data beyond 2 years available and constitute the sample size for the extended phase. Of these patients, 295 patients were successfully consented and enrolled
under the extended-phase study protocol. In the remaining 182
patients, limited 5-year outcome data were obtained in 150 patients and 32 patients who did not provide consent for extended follow-up were considered to be alive on the date of
refusal and then censored, and no additional data were retrieved from these patients.
The baseline characteristics for the treatment group in the
per-protocol population are shown in the Table and are largely
similar between the groups. There were more Black patients
and fewer White patients in the centrifugal-flow pump group
compared with the axial-flow pump group. Baseline demographics were also similar between treatment groups in the destination therapy population. Patients in the centrifugal-flow
pump group had a higher pulmonary vascular resistance and
more mitral regurgitation of any severity compared with patients in the axial-flow pump group, but they were less likely
to be receiving diuretics (eTable 2 in Supplement 2). Demographic information is also prov ided in eTable 3 in
Supplement 2 for the 477 patients who constitute the sample
size for the extended phase.

Composite End Point
The composite of 5-year survival to transplant, recovery, or
LVAD support free of debilitating stroke or reoperation to replace the pump occurred in 336 of 515 patients (65.2%) in the
centrifugal-flow group vs 240 of 505 (47.5%) in the axial-flow
group. The Kaplan-Meier estimates of event-free survival at 5
years were 54.0% in the centrifugal-flow group vs 29.7% in the
axial-flow group (HR, 0.55 [95% CI, 0.45-0.67]; P < .001)
(Figure 2A). The first event type leading to failure of the
jama.com
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Table. Baseline Characteristics in a Study of 5-Year Outcomes
in Patients With Fully Magnetically Levitated vs Axial-Flow
Left Ventricular Assist Devices
No. (%)

Characteristic

Magnetically levitated
centrifugal-flow pump
(n = 515)

Axial-flow pump
(n = 505)

Age, median (IQR), y

62 (52-68)

63 (54-69)

Men

410 (79.6)

413 (81.8)

Women

105 (20.4)

92 (18.2)

Asian

8 (1.6)

3 (0.6)

Black

145 (28.2)

119 (23.6)

Otherb

21 (4.1)

17 (3.4)

Native Hawaiian
or Pacific Islander

0

4 (0.8)

White

341 (66.2)

362 (71.7)

Race and ethnicitya

Hispanic ethnicity

28 (5.4) [n = 514]

27 (5.3)

Body surface area,
mean (SD), m2

2.07 (0.27)

2.08 (0.28)

BMI, median (IQR)

28.4 (24.6-33.0)

27.9 (24.2-32.1)

Ischemic cause
of heart failure

216 (41.9)

236 (46.7)

233 (45.2)

221 (43.8)

Medical history
Diabetes
Atrial fibrillation

215 (41.7)

235 (46.5)

Coronary artery bypass

102 (19.8)

111 (22.0)

Stroke

50 (9.7)

56 (11.1)

Valve replacement/repair

36 (7.0)

30 (5.9)

Mean arterial pressure,
mm Hg

80.1 (10.8)

78.9 (10.0)
[n = 503]

Pulmonary-capillary
wedge pressure,
mm Hg

23 (17-29)
[n = 503]

23 (17-29)
[n = 495]

Cardiac index,
L/min/m2

1.90 (1.60-2.24)
[n = 511]

1.89 (1.60-2.20)
[n = 503]

Pulmonary vascular
resistance, Wood units

2.84 (1.90-4.10)
[n = 498]

2.74 (1.90-3.88)
[n = 493]

Right atrial pressure,
mm Hg

10 (6-15)
[n = 504]

9 (5-15)
[n = 495]

Serum sodium,
mmol/L

136 (133-138)

136 (133-138)

Serum creatinine,
mg/dL

1.29 (1.01-1.61)

1.30 (1.06-1.60)

Estimated glomerular
filtration rate,
mL/min/1.73 m2

58 (43-75)

56 (43-72)

Cardiac function
and pressures,
median (IQR)c

Laboratory values,
median (IQR)d

Intended use of device
Destination therapy

317 (61.6)

307 (60.8)

Bridge to transplant

112 (21.7)

120 (23.8)

Bridge to candidacy
for transplant

86 (16.7)

78 (15.4)

n = 514

n = 501

INTERMACS profilee
1-2

167 (32.5)

159 (31.7)

3

272 (52.9)

251 (50.1)

4-7

75 (14.6)

91 (18.2)
(continued)
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Table. Baseline Characteristics in a Study of 5-Year Outcomes
in Patients With Fully Magnetically Levitated vs Axial-Flow
Left Ventricular Assist Devices (continued)
No. (%)

Characteristic

Magnetically levitated
centrifugal-flow pump
(n = 515)

Valvular insufficiencyf

n = 513

Aortic

Axial-flow pump
(n = 505)

Serious Adverse Events

152 (29.6)

147 (29.1)

11 (2.1)

7 (1.4)

464 (90.4)

439 (86.9)

216 (42.1)

228 (45.1)

431 (84.0)

419 (83.0)

158 (30.8)

127 (25.1)

Inotrope

444 (86.2)

417 (82.6)

Diuretic

435 (84.5)

460 (91.1)

β-blocker

284 (55.1)

269 (53.3)

Angiotensin-converting
enzyme inhibitor
or angiotensin II
receptor antagonist

158 (30.7)

171 (33.9)

64 (12.4)

75 (14.9)

Moderate or severe
Mitral
Moderate or severe
Tricuspid
Moderate or severe
Concomitant medications

Intraaortic balloon pump

Serious adverse event rates from 0 to 5 years are presented in Figure 3 and eTable 5 in Supplement 2. Rates for
hemocompatibility-related adverse events were significantly lower in the centrifugal-flow group compared with
the axial-flow pump group (device thrombosis: 0.010 vs
0.108 events/patient-years; stroke: 0.050 vs 0.136 events/
patient-years; bleeding: 0.430 vs 0.765 events/patientyears). Infection, cardiac arrhythmias, and right ventricular
failure were similar between the groups. Serious adverse
event rates during the extended phase from 2 to 5 years are
shown in eTable 6 in Supplement 2.

Functional Status

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared).
a

Race and ethnicity were self-reported according to the predefined categories
shown.

b

Includes self-reported descriptors such as Hispanic, Latino, Mexican,
Caribbean-American, Middle Eastern, Multi-racial, and Native American.

c

Cardiac function and pressures were evaluated by invasive hemodynamic
assessment. Reference values were as follows: mean arterial pressure,
70-105 mm Hg; pulmonary-capillary wedge pressure, 6-12 mm Hg; cardiac
index, 2.2-4 L/min/m2; pulmonary vascular resistance, ⱕ3 Wood units; right
atrial pressure, 0-5 mm Hg.

d

Laboratory reference values were as follows: serum sodium, 135-145 mmol/L;
serum creatinine, 0.8-1.3 mg/dL; estimated glomerular filtration rate,
>60 mL/min/1.73 m2.

e

Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS) profiles range from 1 to 7; a profile of 1 represents the most
severe illness and a profile of 7 represents the least severe illness. Profiles
range from 1 to 3 in patients requiring inotropic therapy (ranging from unstable
to stable) and 4 to 7 in those without inotropic therapy but with symptoms
including heart failure at rest and advanced New York Heart Association
class III.

f

Moderate and severe valvular insufficiency were determined by the site
investigators based on echocardiography.

composite end point is shown in eTable 4 in Supplement 2.
Censoring of patients who refused consent for extended
follow-up at 2 years (instead of the date of refusal) did not significantly change the 5-year event-free survival rates.

Overall Survival
During the 5-year follow-up period, 156 of 515 patients (30.3%)
in the centrifugal-flow pump group and 184 of 505 (36.4%) in
the axial-flow pump group died. At 5 years, the Kaplan-Meier
overall survival rates were 58.4% in centrifugal-flow pump
group and 43.7% in axial-flow pump group (HR, 0.72 [95% CI,
0.58-0.89]; P = .003) (Figure 2B). In a post hoc analysis, there
were consistent findings in the destination therapy–specific
subgroup, with a 5-year Kaplan-Meier survival rate of 54.8%
1238

in the centrifugal-flow pump group compared with 39.4% in
the axial-flow pump group (HR, 0.70 [95% CI, 0.55-0.90];
P = .005) (eFigure 1 in Supplement 2). Censoring of patients
who refused consent for extended follow-up at 2 years instead of the date of refusal did not significantly change the
5-year survival rates.

Although NYHA class was collected in only 178 patients and
6MWD in only 89 patients at 5 years, the available data showed
similar results between the treatment groups. At 5 years, 74
of 109 patients (67.9%) in the centrifugal-flow pump group and
48 of 69 (69.6%) in the axial-flow pump group were in NYHA
class I or II (eTable 7 in Supplement 2).

Post Hoc End Points and Analyses
Cause-Specific Mortality
The causes of death are shown in eTable 8 in Supplement 2.
In the axial-flow pump group, there were 54 deaths due to hemocompatibility-related adverse events, which were the leading causes of death. In the centrifugal-flow pump group, the
risk of hemocompatibility-related mortality was significantly
lower than in the axial-flow pump group (3.9% vs 10.7%; HR,
0.33 [95% CI, 0.20-0.55]; P < .001), resulting from reduced
strokes and device thrombosis events (Figure 4). Heart failure was the next leading cause of death in both groups, followed by infection. The risk of death due to these causes were
similar between treatment groups.
Competing Outcomes
The outcomes occurring in the centrifugal-flow pump and
axial-flow pump groups during the 5-year study are shown in
eFigure 2 in Supplement 2. At the completion of the 5-year
follow-up, 141 of 515 patients (27.4%) in the centrifugal-flow
pump group and 85 of 505 (16.8%) in the axial-flow pump group
remained receiving LVAD support. Of all 1020 patients, 322
(31.6%) underwent heart transplant. Survival in the presence
of the competing risk of transplant was evaluated with the FineGray model, and the mortality risk continued to remain significantly lower with the centrifugal-flow pump compared with
the axial-flow pump (HR, 0.78 [95% CI, 0.63-0.97]; P = .023).
In the subgroup of patients in whom the intended goal for
therapy was bridge to transplant or bridge to candidacy for
transplant, the transplant rates were 102 of 198 patients (51.5%)
in the centrifugal-flow group and 110 of 198 (55.6%) in the
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Figure 2. Composite End Point and Overall Survival in a Study of 5-Year Outcomes in Patients With Fully Magnetically Levitated
vs Axial-Flow Left Ventricular Assist Devices (LVADs)
A Composite end point

B

Overall survival
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Hazard ratio at 5 y, 0.55 (95% CI, 0.45-0.67); P <.001

0
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Hazard ratio at 5 y, 0.72 (95% CI, 0.58-0.89); P = .003

0
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Time after implant, y
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Centrifugal-flow pump 515
Axial-flow pump
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5

184
124

141
85

Time after implant, y
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A, Comparison of survival to transplant, recovery, or LVAD support free of
debilitating stroke (Modified Rankin Scale score >3) or reoperation to replace
the pump 5 years after the implant. The 5-year event-free survival was 54.0%
(95% CI, 48.5%-59.1%) in the magnetically levitated centrifugal-flow pump
group and 29.7% (95% CI, 24.7%-34.9%) in the axial-flow pump group. Patients
receiving transplants for reason other than device malfunction are censored at
time of transplant assuming there was no prior pump replacement or

138
71

515
505

383
339

289
247

213
165

debilitating stroke. B, Five-year survival was 58.4% (95% CI, 52.8%-63.6%) in
the centrifugal-flow pump group and 43.7% (95% CI, 37.6%-49.6%) in the
axial-flow pump group. Patients who received transplants were censored at
time of transplant. The median (IQR) LVAD support duration was 2.01
(0.94-5.0) years for the centrifugal-flow pump group and 1.86 (0.75-3.98) years
for the axial-flow pump group. In the extended phase after 2 years, a total of
477 patients contributed data to these analyses.

Figure 3. Serious Adverse Events in a Study of 5-Year Outcomes in Patients With Fully Magnetically Levitated
vs Axial-Flow Left Ventricular Assist Devices
Events/patient-years

Serious adverse event

Centrifugal-flow
pump (515 patients;
1234 patient-years)

Axial-flow pump
(505 patients;
997 patient-years)

Rate ratio
(95% CI)

Any bleeding

0.430

0.765

0.56 (0.50-0.63)

<.001

0.252

0.423

0.60 (0.51-0.69)

<.001

Any stroke

0.050

0.136

0.37 (0.27-0.50)

<.001

Suspected or confirmed pump thrombosis

0.010

0.108

0.09 (0.05-0.16)

<.001

Any major infection

0.515

0.551

0.94 (0.83-1.05)

.25

Cardiac arrhythmia

0.207

0.283

0.73 (0.62-0.87)

<.001

Right heart failure

0.149

0.146

1.02 (0.82-1.27)

.87

Other neurologic eventb

0.073

0.065

1.12 (0.81-1.54)

.49

Gastrointestinal bleeding

Favors
centrifugal-flow
pump

0.05

0.1

Favors
axial-flow
pump

1

P valuea

4

Rate ratio (95% CI)

Serious adverse events are defined as those causing death or congenital
abnormality or birth defect or a life-threatening illness or injury that results in
permanent disability, requires hospitalization, or prolongs a hospitalization
and/or requires intervention to prevent permanent injury or damage.
Serious adverse events occurring after 2 years were collected in 178 patients in
the magnetically levitated centrifugal-flow pump group and 117 patients in the

axial-flow pump group (eFigure 3 in Supplement 2). Of these
396 patients, 85 (21.5%) died before receiving a transplant. In
addition, a portion of patients in whom the initial goal for
therapy was destination therapy (54 of 317 [17.0%] in the centrifugal-flow pump group and 56 of 307 [18.2%] in the axialflow pump group) were eventually put on a transplant list and
received a transplant (eFigure 4 in Supplement 2). Because
some patients in whom the intended goal was destination
therapy ultimately received a transplant, survival was reevalujama.com

axial-flow pump group. Other secondary end points are shown in eTable 6 and 7
in Supplement.
a

Rate ratios and P value from Poisson regression.

b

Includes encephalopathy, seizure, transient ischemic attack, and other
neurological events other than stroke.

ated in the destination therapy subgroup excluding patients
who received a transplant (eFigure 5 in Supplement 2). In this
subgroup of patients who underwent destination therapy, a significant survival benefit with the centrifugal-flow pump was
demonstrated (HR, 0.70 [95% CI, 0.55-0.89]; P = .004).
Subgroup Analysis of Survival
No significant interaction between the groups was observed
for the prespecified subgroups of age, sex, race and ethnicity,
(Reprinted) JAMA September 27, 2022 Volume 328, Number 12
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Figure 4. Cause-Specific Mortality 5 Years After Implant in a Study of Patients With Fully Magnetically Levitated
vs Axial-Flow Left Ventricular Assist Devices
No. (%)

Favors
centrifugal-flow
pump

Favors
axial-flow
pump

Centrifugal-flow
pump (n = 515)

Axial-flow
pump (n = 505)

Difference, %
(95% CI) %a

Hazard ratio
(95% CI)

Hemocompatibility-related event
(device thrombosis, stroke, bleeding)

20 (3.9)

54 (10.7)

–6.8 (–10.0 to -3.6)

0.33 (0.20-0.55)

<.001

Heart failure

47 (9.1)

43 (8.5)

0.6 (–2.9 to 4.1)

1.01 (0.67-1.53)

.95

Infection

26 (5.0)

26 (5.1)

–0.1 (–2.8 to 2.6)

0.92 (0.54-1.59)

.77

Otherc

63 (12.2)

61 (12.1)

0.0 (–4.1 to 4.0)

0.94 (0.66-1.33)

.72

Cause of death

0.2

1

P valueb

2

Hazard ratio (95% CI)

Comparison of deaths due to hemocompatibility-related events, heart failure,
infection, and other causes. In the extended phase after 2 years, a total of 477
patients contributed data to the analysis.
a

Difference shown for magnetically levitated centrifugal-flow pump minus
axial-flow pump values.

intended goal of pump support (bridge to transplant or destination therapy), or INTERMACS profile with regard to overall survival (eFigure 6 in Supplement 2). Thus, the treatment effect with
respect to survival was consistent across different subgroups.
Tipping Point Sensitivity Analysis
The tipping point δ was between 3 and 4, which indicated that
the mortality hazard of the patients in the centrifugal-flow
pump group that were withdrawn would have to be at least
3-fold greater than those who were not withdrawn to abolish
the centrifugal-flow pump survival benefit compared with the
axial-flow pump.

Discussion
In this observational follow-up study of patients from the IDE
trial, per-protocol analyses found that implantation of a fully
magnetically levitated LVAD vs axial-flow LVAD was associated with a better composite outcome and higher likelihood
of overall survival at 5 years. These findings support the use
of the fully magnetically levitated LVAD.
Unlike the pivotal 2-year analysis, there was higher likelihood of overall survival in patients who received the centrifugal-flow pump compared with the axial-flow pump at this
5-year time point. The statistically significant difference in survival was attributable to fewer deaths due to hemocompatibility-related adverse events, including stroke, bleeding, and
pump thrombosis. The median survival in patients in the centrifugal-flow pump group with advanced heart failure exceeded 5 years, including the subgroup who received an LVAD
with a therapeutic intent of destination therapy and were
deemed ineligible for cardiac transplant at the time of enrollment in the trial.
Engineering advances have introduced technologically
improved LVADs in the past 2 decades with a gain in 2-year
survival. 3,6,7 The Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure
(REMATCH) trial investigated an early-generation LVAD
1240

b

Hazard ratios and P values were calculated from the Fine-Gray model.

c

Other causes are provided in eTable 8 in Supplement 2. The most common
other causes included ventricular arrhythmia or cardiac arrest, trauma, hepatic
or kidney failure, respiratory failure, and driveline or power cable
disconnection.

(HeartMate vented electric device, Thoratec) compared with
optimal medical therapy and demonstrated a 23% survival
with the LVAD at 2 years. 8 This represented a marked
improvement over that expected in a cohort of transplantineligible patients with advanced heart failure (8% survival at
2-year in the medical therapy group). A randomized clinical
trial of a continuous-flow pump compared with the oldergeneration pulsatile-flow LVAD used in the REMATCH trial
demonstrated a significant improvement in survival of 58%
at 2 years. 9 Another centrifugal-flow pump that did not
require an abdominal surgical pocket and could be implanted
directly in the thorax, the Heartware HVAD (Medtronic) was
deemed to be noninferior to the axial-flow pump with a similar survival at 2 years.10 However, these devices have had
hemocompatibility-related adverse events, with a dominance
of pump thrombosis in the axial-flow pump group and stroke
events in the HVAD group.11,12 The centrifugal-flow pump
was engineered to reduce hemocompatibility-related adverse
events by increasing the blood flow pathways and developing
an intrinsic pulsatility in the pump while using a frictionless
fully magnetically levitated rotor system.13-15
Until this trial, registry analyses such as INTERMACS have
provided the best look at 5-year survival, but their analyses
have been dominated by devices other than the centrifugalflow pump. Estimates from those analyses indicated an overall survival of 48.2% in the current era, but lower, at 40.6%,
in the destination therapy subgroup at 5 years.16,17 These survival estimates are concordant with the observed survival in
the axial-flow pump group in the current trial.
In the current trial, adverse events and deaths due to heart
failure, followed by infection, remained dominant with the centrifugal-flow pump LVAD. There continues to be concerns about
hemodynamic-related adverse events (heart failure) and morbidity of device-related infection.18-20 Clinical algorithms that
utilize invasive hemodynamic assessments in concert with cardiac and device-based imaging may be required to discriminate the associated causes of heart failure and to target therapy
toward the primary underlying deficit.17 These may include
speed adjustments to facilitate left ventricular unloading,
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amelioration of aortic regurgitation (which can result in recirculation), or assessing for defects such as obstruction of the
outflow graft. Dealing with driveline-related infections may require engineering of fully internalized power sources through
transcutaneous energy transfer or other techniques.3

Limitations
This study has several limitations. First, as a result of the operational challenges in this trial due to the gap between completion of the pivotal trial, the need to initiate a separate study
protocol, and challenges encountered due to the unanticipated occurrence of the COVID-19 pandemic, there was a high
percentage of missing data for the originally intended primary end point and serious adverse events. This required modifying the principal end point analysis to focus on survival,
which provided the most complete information in this study.
However, the rates of nonfatal events in end points should be
interpreted carefully due to the magnitude and imbalance of
missingness of values between the treatment groups. Second, data to define the accompanying quality of life experienced during device therapy were not collected, making cost-
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